Skip to search formSkip to main contentSkip to account menu

IMGN853

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Grade 3 endometrioid and uterine serous carcinomas (USC) account for the vast majority of endometrial cancer deaths. The purpose… 
Highly Cited
2017
Highly Cited
2017
Purpose This phase I expansion cohort study evaluated the safety and clinical activity of mirvetuximab soravtansine (IMGN853), an… 
Highly Cited
2017
Highly Cited
2017
Mirvetuximab soravtansine (IMGN853) is an antibody‐drug conjugate that selectively targets folate receptor α (FRα). In this phase… 
2017
2017
5547Background: The early clinical evaluation of mirvetuximab soravtansine (IMGN853), an ADC that comprises a FRα-binding… 
2016
2016
5567Background: IMGN853 (mirvetuximab soravtansine) is an ADC, comprising a FRα-binding antibody linked to the tubulin-disrupting… 
Highly Cited
2015
Highly Cited
2015
A majority of ovarian and non–small cell lung adenocarcinoma cancers overexpress folate receptor α (FRα). Here, we report the… 
Review
2015
Review
2015
Despite advances in the development of molecularly targeted therapies, limited improvements in overall survival have been noted… 
2015
2015
5518 Background: IMGN853 (mirvetuximab soravtansine) is a FRα-targeting ADC that comprises a FRα-binding antibody conjugated with… 
2014
2014
5571 Background: IMGN853 is a FRα-targeting ADC that comprises a FRa-binding antibody conjugated with the potent maytansinoid…